{"id":99232,"date":"2024-04-05T15:58:00","date_gmt":"2024-04-05T13:58:00","guid":{"rendered":"https:\/\/cms.munich-startup.net\/?p=99232"},"modified":"2024-04-03T15:26:44","modified_gmt":"2024-04-03T13:26:44","slug":"eisbach-bio-receives-42-million-euros","status":"publish","type":"post","link":"https:\/\/cms.munich-startup.net\/en\/99232\/eisbach-bio-receives-42-million-euros\/","title":{"rendered":"Eisbach Bio receives 4.2 million euros"},"content":{"rendered":"<div class=\"entry-content\">\n<p>Eisbach Bio is working on a new class of cancer drugs. These drugs use specific molecules to interfere with the internal mechanisms of cancer cells and block their function. This makes it possible to combat tumors that are resistant to conventional treatments because their <a href=\"https:\/\/www.eisbach.bio\/#science\" target=\"_blank\" rel=\"noreferrer noopener\">Genome constantly changing<\/a>This commitment is worth 4.2 million euros (4.5 million dollars) to the Cancer Focus Fund.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p>\u201cEisbach\u2019s distinctive and scientifically sophisticated approach to treating common, difficult-to-treat cancers fits perfectly with our goals at the Cancer Focus Fund,\u201d<\/p><\/blockquote>\n\n\n\n<p>says <strong>Ross Barrett<\/strong>, Founder and Managing Partner of the Cancer Focus Fund.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Eisbach Bio starts clinical study<\/h2>\n\n\n\n<p>The US investment fund was established in collaboration with the University of Texas MD Anderson Cancer Center (MD Anderson) to advance promising cancer therapies. The investment will finance a Phase 1\/2 clinical trial of Eisbach Bio&#039;s lead candidate, EIS-12656. <a href=\"\/en\/?s=eisbach+bio\">Startup<\/a> plans to conduct the study for the treatment of refractory advanced solid tumors at MD Anderson.<\/p>\n\n\n\n<p>Regarding the investment <strong>Barrett<\/strong>:<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p>&quot;We want to support innovative young companies like Eisbach in rapidly advancing exceptionally promising new cancer drugs into clinical trials with the help of MD Anderson&#039;s experienced researchers and clinicians. EIS-12656 has demonstrated the potential to treat many recurrent and refractory tumors more effectively and with fewer side effects than current therapies, and we look forward to following the progress of this exciting first-in-class compound in clinical development. We are also pleased to expand our geographic reach with this first investment in a German-based biotech company with its rich history of biomedical innovation.&quot;<\/p><\/blockquote>\n\n\n\n<p><strong>Dr. Andreas Ladurner<\/strong>, founder and CSO of Eisbach and Professor and Chair of Physiological Chemistry at the Ludwig Maximilian University of Munich, comments:<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p>&quot;Most cancers contain mechanisms for genome reorganization that play a crucial and very specific role in tumor biology. If we discover how each of these vital mechanisms is selectively regulated, we can exploit unique molecular vulnerabilities. This approach holds great promise for the discovery of new cancer drugs that are both selective and safe.&quot;<\/p><\/blockquote>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>The biotech company Eisbach Bio is receiving support from Texas: The Cancer Focus Fund is investing \u20ac4.2 million ($4.5 million) in the Munich-based startup. The money will go directly to a clinical trial for the treatment of human tumors.<\/p>","protected":false},"author":42,"featured_media":77671,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5633,1],"tags":[371,4344,52],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Eisbach Bio erh\u00e4lt 4,2 Millionen Euro - Munich Startup<\/title>\n<meta name=\"description\" content=\"Das Biotech-Unternehmen Eisbach Bio bekommt Unterst\u00fctzung aus Texas: Der Cancer Focus Fund investiert 4,2 Millionen Euro (4,5 Millionen Dollar).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cms.munich-startup.net\/en\/99232\/eisbach-bio-receives-42-million-euros\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eisbach Bio erh\u00e4lt 4,2 Millionen Euro - Munich Startup\" \/>\n<meta property=\"og:description\" content=\"Das Biotech-Unternehmen Eisbach Bio bekommt Unterst\u00fctzung aus Texas: Der Cancer Focus Fund investiert 4,2 Millionen Euro (4,5 Millionen Dollar).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cms.munich-startup.net\/en\/99232\/eisbach-bio-receives-42-million-euros\/\" \/>\n<meta property=\"og:site_name\" content=\"Munich Startup\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/munichstartup\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-05T13:58:00+00:00\" \/>\n<meta name=\"author\" content=\"Saskia Doll\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:site\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Saskia Doll\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cms.munich-startup.net\/99232\/eisbach-bio-erhaelt-42-millionen-euro\/\",\"url\":\"https:\/\/cms.munich-startup.net\/99232\/eisbach-bio-erhaelt-42-millionen-euro\/\",\"name\":\"Eisbach Bio erh\u00e4lt 4,2 Millionen Euro - Munich Startup\",\"isPartOf\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cms.munich-startup.net\/99232\/eisbach-bio-erhaelt-42-millionen-euro\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cms.munich-startup.net\/99232\/eisbach-bio-erhaelt-42-millionen-euro\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2021\/11\/DZ6_6744.jpg\",\"datePublished\":\"2024-04-05T13:58:00+00:00\",\"author\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/a297bffde6879f56c9ff7b04d9af60b5\"},\"description\":\"Das Biotech-Unternehmen Eisbach Bio bekommt Unterst\u00fctzung aus Texas: Der Cancer Focus Fund investiert 4,2 Millionen Euro (4,5 Millionen Dollar).\",\"breadcrumb\":{\"@id\":\"https:\/\/cms.munich-startup.net\/99232\/eisbach-bio-erhaelt-42-millionen-euro\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cms.munich-startup.net\/99232\/eisbach-bio-erhaelt-42-millionen-euro\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/99232\/eisbach-bio-erhaelt-42-millionen-euro\/#primaryimage\",\"url\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2021\/11\/DZ6_6744.jpg\",\"contentUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2021\/11\/DZ6_6744.jpg\",\"width\":2400,\"height\":1597,\"caption\":\"Adrian Schomburg, CEO bei Eisbach Bio\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cms.munich-startup.net\/99232\/eisbach-bio-erhaelt-42-millionen-euro\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cms.munich-startup.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eisbach Bio erh\u00e4lt 4,2 Millionen Euro\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cms.munich-startup.net\/#website\",\"url\":\"https:\/\/cms.munich-startup.net\/\",\"name\":\"Munich Startup\",\"description\":\"Das offizielle Startup-Portal f\u00fcr M\u00fcnchen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cms.munich-startup.net\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/a297bffde6879f56c9ff7b04d9af60b5\",\"name\":\"Saskia Doll\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3cbbe2dd459d277864bc6c7477d0bdf8?s=96&d=blank&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3cbbe2dd459d277864bc6c7477d0bdf8?s=96&d=blank&r=g\",\"caption\":\"Saskia Doll\"},\"url\":\"https:\/\/cms.munich-startup.net\/en\/author\/doll\/\"}]}<\/script>\n<meta property=\"og:image\" content=\"https:\/\/cms.munich-startup.net\/en\/wp-content\/uploads\/2021\/11\/DZ6_6744.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2400\" \/>\n\t<meta property=\"og:image:height\" content=\"1597\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eisbach Bio receives 4.2 million euros - Munich Startup","description":"The biotech company Eisbach Bio is receiving support from Texas: The Cancer Focus Fund is investing 4.2 million euros (4.5 million dollars).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cms.munich-startup.net\/en\/99232\/eisbach-bio-receives-42-million-euros\/","og_locale":"en_US","og_type":"article","og_title":"Eisbach Bio erh\u00e4lt 4,2 Millionen Euro - Munich Startup","og_description":"Das Biotech-Unternehmen Eisbach Bio bekommt Unterst\u00fctzung aus Texas: Der Cancer Focus Fund investiert 4,2 Millionen Euro (4,5 Millionen Dollar).","og_url":"https:\/\/cms.munich-startup.net\/en\/99232\/eisbach-bio-receives-42-million-euros\/","og_site_name":"Munich Startup","article_publisher":"https:\/\/www.facebook.com\/munichstartup\/","article_published_time":"2024-04-05T13:58:00+00:00","author":"Saskia Doll","twitter_card":"summary_large_image","twitter_creator":"@munich_startup","twitter_site":"@munich_startup","twitter_misc":{"Written by":"Saskia Doll","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cms.munich-startup.net\/99232\/eisbach-bio-erhaelt-42-millionen-euro\/","url":"https:\/\/cms.munich-startup.net\/99232\/eisbach-bio-erhaelt-42-millionen-euro\/","name":"Eisbach Bio receives 4.2 million euros - Munich Startup","isPartOf":{"@id":"https:\/\/cms.munich-startup.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cms.munich-startup.net\/99232\/eisbach-bio-erhaelt-42-millionen-euro\/#primaryimage"},"image":{"@id":"https:\/\/cms.munich-startup.net\/99232\/eisbach-bio-erhaelt-42-millionen-euro\/#primaryimage"},"thumbnailUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2021\/11\/DZ6_6744.jpg","datePublished":"2024-04-05T13:58:00+00:00","author":{"@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/a297bffde6879f56c9ff7b04d9af60b5"},"description":"The biotech company Eisbach Bio is receiving support from Texas: The Cancer Focus Fund is investing 4.2 million euros (4.5 million dollars).","breadcrumb":{"@id":"https:\/\/cms.munich-startup.net\/99232\/eisbach-bio-erhaelt-42-millionen-euro\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cms.munich-startup.net\/99232\/eisbach-bio-erhaelt-42-millionen-euro\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/99232\/eisbach-bio-erhaelt-42-millionen-euro\/#primaryimage","url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2021\/11\/DZ6_6744.jpg","contentUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2021\/11\/DZ6_6744.jpg","width":2400,"height":1597,"caption":"Adrian Schomburg, CEO bei Eisbach Bio"},{"@type":"BreadcrumbList","@id":"https:\/\/cms.munich-startup.net\/99232\/eisbach-bio-erhaelt-42-millionen-euro\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cms.munich-startup.net\/"},{"@type":"ListItem","position":2,"name":"Eisbach Bio erh\u00e4lt 4,2 Millionen Euro"}]},{"@type":"WebSite","@id":"https:\/\/cms.munich-startup.net\/#website","url":"https:\/\/cms.munich-startup.net\/","name":"Munich Startup","description":"The official startup portal for Munich","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cms.munich-startup.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/a297bffde6879f56c9ff7b04d9af60b5","name":"Saskia Doll","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3cbbe2dd459d277864bc6c7477d0bdf8?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3cbbe2dd459d277864bc6c7477d0bdf8?s=96&d=blank&r=g","caption":"Saskia Doll"},"url":"https:\/\/cms.munich-startup.net\/en\/author\/doll\/"}]},"og_image":[{"width":2400,"height":1597,"url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2021\/11\/DZ6_6744.jpg","type":"image\/jpeg"}]},"_showyear":"","_inactive":"","_show_financing":"","_hide_on_map":"","_edit_lock":"1712152541:24","_edit_last":"42","_yoast_wpseo_focuskw":"Eisbach Bio","_yoast_wpseo_metadesc":"Das Biotech-Unternehmen Eisbach Bio bekommt Unterst\u00fctzung aus Texas: Der Cancer Focus Fund investiert 4,2 Millionen Euro (4,5 Millionen Dollar).","_yoast_wpseo_linkdex":"82","_thumbnail_id":"77671","wbounce_status":"default","_yoast_wpseo_primary_category":"5633","_yoast_wpseo_focuskw_text_input":"","_yoast_wpseo_content_score":"60","ms_image_format":"contentwidth","_ms_image_format":"field_5cb8587572c8b","ms_dachzeile":"","_ms_dachzeile":"field_5cd9b7f365df5","ms_bump_post_date":"","_ms_bump_post_date":"field_5d1341edcf42a","guest_author_name":"","_guest_author_name":"field_5cee78a6016f9","guest_author_image":"","_guest_author_image":"field_5cee7914016fb","guest_author_description":"","_guest_author_description":"field_5cee78dd016fa","ms_post_image_caption":"","_ms_post_image_caption":"field_5f735b0735284","ms_post_image_credit":"","_ms_post_image_credit":"field_5f735b1435285","suppress_startupbox":"0","_suppress_startupbox":"field_60a64b0b6efc6","_yoast_wpseo_estimated-reading-time-minutes":"2","_wp_old_date":"","_yoast_wpseo_title":"","_yoast_wpseo_wordproof_timestamp":"","footnotes":"","easy_language_simplification_original_id":"","easy_language_source_language":"","easy_language_simplification_language":"","easy_language_api":"","easy_language_prevent_automatic_mode":"","_wp_old_slug":"","_wp_trash_meta_status":"","_wp_trash_meta_time":"","easy_language_simplification_state_changed_from":"","easy_language_de_EL_changed":"","ms_competition_deadline":"","_ms_competition_deadline":"","_wpbitly":"","enclosure":"","_yoast_wpseo_meta-robots-noindex":"","_yoast_wpseo_meta-robots-nofollow":"","wbounce_template":"","wbounce_title":"","wbounce_text":"","wbounce_cta":"","wbounce_url":"","wbounce_override":"","_yoast_wpseo_opengraph-title":"","_yoast_wpseo_opengraph-description":"","_oembed_7131efca3705e16bd9da2c41df237660":"","_oembed_time_7131efca3705e16bd9da2c41df237660":"","_pprredirect_type":"","_pprredirect_url":"","_yoast_wpseo_opengraph-image":"","_yoast_wpseo_opengraph-image-id":"","_newsletterglue":"","easy_language_text_language":"","_wp_desired_post_slug":"","_relevanssi_noindex_reason":"","_links":{"self":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/99232"}],"collection":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/users\/42"}],"replies":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/comments?post=99232"}],"version-history":[{"count":2,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/99232\/revisions"}],"predecessor-version":[{"id":99234,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/99232\/revisions\/99234"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media\/77671"}],"wp:attachment":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media?parent=99232"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/categories?post=99232"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/tags?post=99232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}